^
    6d
    A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=150, Active, not recruiting, AbbVie | Trial completion date: Nov 2023 --> Sep 2024 | Trial primary completion date: Nov 2023 --> Sep 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PD-L1 negative
    |
    carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
    14d
    Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis (clinicaltrials.gov)
    P1/2, N=40, Completed, AbbVie | Active, not recruiting --> Completed | Phase classification: P1b/2 --> P1/2
    Trial completion • Phase classification • Adverse events • Combination therapy • Metastases
    |
    5-fluorouracil • oxaliplatin • irinotecan • budigalimab (ABBV-181) • leucovorin calcium • giloralimab (ABBV-927)
    11ms
    Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis (clinicaltrials.gov)
    P1b/2, N=129, Recruiting, AbbVie | Trial completion date: Jun 2025 --> Dec 2024 | Trial primary completion date: Aug 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Adverse events • Combination therapy • Metastases
    |
    5-fluorouracil • oxaliplatin • irinotecan • budigalimab (ABBV-181) • leucovorin calcium • giloralimab (ABBV-927)
    over1year
    A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=150, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PD-L1 negative
    |
    carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
    over1year
    A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, AbbVie | Trial completion date: Jul 2024 --> Nov 2023
    Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PD-L1 negative
    |
    carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
    almost2years
    A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, AbbVie | Trial completion date: Dec 2023 --> Jul 2024
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PD-L1 negative
    |
    carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
    almost3years
    Current status of intralesional agents in treatment of malignant melanoma. (PubMed, Ann Transl Med)
    This review focuses on the current status of IT agents currently under clinical trials in melanoma. Reviewed therapies include T-VEC, T-VEC with immune checkpoint inhibitors including ipilimumab and pembrolizumab or other agents, RP1, OrienX010, Canerpaturev (C-REV, HF10), CAVATAK (coxsackievirus A21, CVA21) alone or in combination with checkpoint inhibitors, oncolytic polio/rhinovirus recombinant (PVSRIPO), MAGE-A3-expressing MG1 Maraba virus, VSV-IFNbetaTYRP1, suicide gene therapy, ONCOS-102, OBP-301 (Telomelysin), Stimulation of Interferon Genes Pathway (STING agonists) including DMXAA, MIW815 (ADU-S100) and MK-1454, PV-10, toll-like receptors (TLRs) agonists including TLR-9 agonists (SD-101, CMP-001, IMO-2125 or tilsotolimod, AST-008 or cavrotolimod, MGN1703 or lefitolimod), CV8102, NKTR-262 plus NKTR-214, LHC165, G100, intralesional interleukin-2, Daromun (L19IL2 plus L19TNF), Hiltonol (poly-ICLC), electroporation including calcium electroporation and plasmid interleukin-12 electroporation (pIL-12 EP), IT ipilimumab, INT230-6 (cisplatin and vinblastine with an amphiphilic penetration enhancer), TTI-621 (SIRPαFc), CD-40 agonistic antibodies (ABBV-927 and APX005M), antimicrobial peptide LL37 and other miscellaneous agents.
    Review • Journal
    |
    TYRP1 (Tyrosinase Related Protein 1) • CD40 (CD40 Molecule) • MAGEA3 (MAGE Family Member A3)
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • Imlygic (talimogene laherparepvec) • bempegaldesleukin (NKTR-214) • vidutolimod (CMP-001) • Fibromun (onfekafusp alfa) • ONCOS-102 • cavrotolimod (AST-008) • cisplatin/vinblastine/SHAO-FA (INT230-6) • nelitolimod (SD-101) • ADU-S100 • CV8102 • Cavatak (gebasaxturev) • Hiltonol (poly-ICLC) • LHC165 • NKTR-262 • Nidlegy (darleukin/fibromun) • OrienX010 • Telomelysin (suratadenoturev) • canerpaturev (TBI-1401) • giloralimab (ABBV-927) • lefitolimod (MGN1703) • sotigalimab (PYX-107) • tilsotolimod (IMO-2125) • ulevostinag (MK-1454)
    over3years
    A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, AbbVie | Trial primary completion date: May 2023 --> Nov 2023
    Clinical • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PD-L1 negative
    |
    carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
    4years
    [VIRTUAL] A phase I study of CD40 agonist ABBV-927 plus OX40 agonist ABBV-368 with or without the PD-1 inhibitor budigalimab in patients with advanced solid tumors. (ASCO 2020)
    Screening began on 21 May 2019, and enrollment is ongoing. Research Funding: Abbvie, Inc
    Clinical • P1 data
    |
    TNFRSF4 (TNF Receptor Superfamily Member 4) • CD40 (CD40 Molecule)
    |
    budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)